101 related articles for article (PubMed ID: 19049710)
1. Gadolinium nephrotoxicity: case report of a rare entity and review of the literature.
Badero OJ; Schlanger L; Rizk D
Clin Nephrol; 2008 Dec; 70(6):518-22. PubMed ID: 19049710
[TBL] [Abstract][Full Text] [Related]
2. Negligible Risk of Acute Renal Failure Among Hospitalized Patients After Contrast-Enhanced Imaging With Iodinated Versus Gadolinium-Based Agents.
Gorelik Y; Yaseen H; Heyman SN; Khamaisi M
Invest Radiol; 2019 May; 54(5):312-318. PubMed ID: 30480553
[TBL] [Abstract][Full Text] [Related]
3. Can gadolinium be safely given in renal failure?
Weissleder R
AJR Am J Roentgenol; 1996 Jul; 167(1):278-9. PubMed ID: 8659405
[No Abstract] [Full Text] [Related]
4. Acute renal failure after arteriography with a gadolinium-based contrast agent.
Gemery J; Idelson B; Reid S; Yucel EK; Pagan-Marin H; Ali S; Casserly L
AJR Am J Roentgenol; 1998 Nov; 171(5):1277-8. PubMed ID: 9798860
[No Abstract] [Full Text] [Related]
5. Imaging patients with kidney disease: how do we approach contrast-related toxicity?
Perazella MA; Reilly RF
Am J Med Sci; 2011 Mar; 341(3):215-21. PubMed ID: 21139495
[TBL] [Abstract][Full Text] [Related]
6. Risk of acute kidney injury after exposure to gadolinium-based contrast in patients with renal impairment.
Chien CC; Wang HY; Wang JJ; Kan WC; Chien TW; Lin CY; Su SB
Ren Fail; 2011; 33(8):758-64. PubMed ID: 21777176
[TBL] [Abstract][Full Text] [Related]
7. Nephrotoxicity of gadolinium-based contrast in the setting of renal artery intervention: retrospective analysis with 10-year follow-up.
Takahashi EA; Kallmes DF; Mara KC; Harmsen WS; Misra S
Diagn Interv Radiol; 2018 Nov; 24(6):378-384. PubMed ID: 30406762
[TBL] [Abstract][Full Text] [Related]
8. Peripheral vascular disease evaluated with reduced-dose gadolinium-enhanced MR angiography.
Rofsky NM; Johnson G; Adelman MA; Rosen RJ; Krinsky GA; Weinreb JC
Radiology; 1997 Oct; 205(1):163-9. PubMed ID: 9314979
[TBL] [Abstract][Full Text] [Related]
9. Nephrogenic systemic fibrosis in Japan: advisability of keeping the administered dose as low as possible.
Tsushima Y; Takahashi-Taketomi A; Endo K
Radiology; 2008 Jun; 247(3):915-6. PubMed ID: 18487548
[No Abstract] [Full Text] [Related]
10. [Contrast-enhanced MR angiography (CEMRA) in peripheral arterial occlusive disease (PAOD): conventional moving table technique versus hybrid technique].
von Kalle T; Gerlach A; Hatopp A; Klinger S; Prodehl P; Arlart IP
Rofo; 2004 Jan; 176(1):62-9. PubMed ID: 14712408
[TBL] [Abstract][Full Text] [Related]
11. Detection of renal dysfunction by point-of-care creatinine testing in patients undergoing peripheral MR angiography.
Kalisz KR; Davarpanah AH; Usman AA; Collins JD; Carroll TJ; Carr JC
AJR Am J Roentgenol; 2011 Aug; 197(2):430-5. PubMed ID: 21785090
[TBL] [Abstract][Full Text] [Related]
12. Severe adverse reactions with contrast agents for magnetic resonance: clinical experience in 30,000 MR examinations.
De Ridder F; De Maeseneer M; Stadnik T; Luypaert R; Osteaux M
JBR-BTR; 2001 Aug; 84(4):150-2. PubMed ID: 11688727
[TBL] [Abstract][Full Text] [Related]
13. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
[TBL] [Abstract][Full Text] [Related]
14. Gadolinium-Induced Fibrosis.
Todd DJ; Kay J
Annu Rev Med; 2016; 67():273-91. PubMed ID: 26768242
[TBL] [Abstract][Full Text] [Related]
15. Gadolinium induced recurrent acute pancreatitis.
Blasco-Perrin H; Glaser B; Pienkowski M; Peron JM; Payen JL
Pancreatology; 2013; 13(1):88-9. PubMed ID: 23395575
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance angiography: current status in the planning and follow-up of endovascular treatment in lower-limb arterial disease.
Lakshminarayan R; Simpson JO; Ettles DF
Cardiovasc Intervent Radiol; 2009 May; 32(3):397-405. PubMed ID: 19130124
[TBL] [Abstract][Full Text] [Related]
17. Anaphylactic shock after first exposure to a macrocyclic gadolinium chelate: a few comments.
Idée JM; Corot C
J Allergy Clin Immunol; 2008 Jul; 122(1):215-6; author reply 216-7. PubMed ID: 18547628
[No Abstract] [Full Text] [Related]
18. Fatal anaphylaxis caused by gadolinium due to beta-tryptase-induced hemorragic diathesis.
Prieto-García A; Pérez-David E; Devesa C; Tornero P; Schwartz LB; Pascual C; Castells MC
J Allergy Clin Immunol Pract; 2017; 5(5):1433-1434. PubMed ID: 28634099
[No Abstract] [Full Text] [Related]
19. Incidence of immediate gadolinium contrast media reactions.
Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
[TBL] [Abstract][Full Text] [Related]
20. Gadoteridol-induced anaphylaxis - not a class allergy.
Galera C; Pur Ozygit L; Cavigioli S; Bousquet PJ; Demoly P
Allergy; 2010 Jan; 65(1):132-4. PubMed ID: 19796195
[No Abstract] [Full Text] [Related]
[Next] [New Search]
